Oura Eyes Up to $3 Billion IPO at $16 Billion-Plus Valuation
Oura Health Oy, the Finnish company behind the Oura Ring smart ring, is planning to raise up to $3 billion in a U.S. initial public offering as soon as September 2026, with a valuation that could exceed $16 billion, according to Bloomberg. A significant portion of the shares sold will come from existing investors looking to cash out, not just from new shares issued by the company itself.
A $16 billion valuation would be a roughly 47% jump over the $10.9 billion figure assigned to Oura in September 2025, when the company closed an $875 million Series E round (a late-stage funding round for private companies) backed by Fidelity, ICONIQ, Whale Rock, and Atreides. That round more than doubled the $5 billion valuation Oura received in a 2024 funding round. Earlier backers include Dexcom, The Chernin Group, Forerunner Ventures, Coatue, and Temasek. TechCrunch
Oura confidentially submitted its S-1 filing — the registration document companies must file with U.S. regulators before going public — to the Securities and Exchange Commission in May 2026, as the company confirmed at the time. The confidential process lets a company refine its public disclosures out of the spotlight, a route increasingly favored by late-stage private companies testing whether investors will bite. The August 2026 Bloomberg report, detailing the $3 billion raise target and the $16 billion-plus valuation, is the first indication of the offering's scale.
The company, with offices in San Francisco and Finland and more than 900 employees, makes smart rings that track health, fitness, and sleep data. The ring form factor, rather than the wrist-worn bands and watches that dominate wearables, has been Oura's core differentiator since the product launched. The category is now drawing larger hardware players: Samsung launched its Galaxy Ring roughly two years before August 2026, bringing a vertically integrated competitor — meaning Samsung controls both the hardware and the software ecosystem — into a space Oura had largely occupied alone.
Oura's most direct rival in the wearables space is Whoop, the fitness band maker whose valuation rose to $10 billion in March 2026 following its own Series G fundraising round. The two companies sit in adjacent but distinct positions: Oura's ring focuses on continuous biometric monitoring (ongoing measurement of body signals like heart rate and temperature) with an emphasis on sleep and recovery, while Whoop's band centers on strain tracking and subscription-based coaching. Both have reached valuations in the ten-figure range, and both are positioning themselves as the wearable category narrows from general-purpose smartwatches toward specialized health and performance devices.
The $3 billion raise target, if achieved, would place Oura among the larger technology IPOs of 2026. The inclusion of a large secondary component — existing shareholders selling stock alongside the company's new issuance — is worth noting. In my view, a large secondary block in a debut offering can signal that early backers are seeking liquidity at what they consider a valuation peak, or at least a level they are unwilling to wait out. It can also ease pricing tension by increasing the float, or the number of shares available for public trading, without further diluting the company's ownership structure, since secondary shares do not add to the share count from the company's perspective. How the split between primary and secondary shares ultimately breaks down will be a detail worth watching when the S-1 goes public.
The valuation trajectory itself tells a story. Oura went from $5 billion in 2024 to $11 billion in September 2025 to a potential $16 billion a year later. That arc reflects real hardware and revenue growth, and also a market that has, so far, stayed receptive to consumer hardware companies whose health data creates a competitive moat — a durable advantage that is hard for rivals to replicate. The question a prospective IPO buyer needs to weigh is whether the jump from $11 billion to $16 billion in twelve months is supported by comparable growth in the underlying business, or whether it reflects the premium that public-market demand for health data with AI applications might command in the current cycle.
The competitive landscape also matters for how the public offering will be received. Samsung's entry means Oura is no longer the sole player in the ring form factor, and Apple's well-reported interest in health-oriented wearables, while not directly confirmed for a ring device, casts a shadow over any standalone hardware company's long-term defensibility. Whoop's parallel path, with a $10 billion private valuation and deep capital reserves, means the two could end up competing for the same public-market dollar if Whoop also moves toward an IPO.
None of these factors are disqualifying. But they frame what a $16 billion valuation is being asked to absorb: a larger, well-capitalized competitor in the same form factor, a direct rival at a similar scale, and a hardware category that has historically been brutal to standalone players once the platform giants commit. Oura's S-1, when it goes public, will need to make the case that its data and software ecosystem, not the ring itself, is the durable asset.
